Tuesday, May 16, 2023 9:11:18 AM
NOTIFICATION OF LATE FILING
Name of the Issuer:
Annual Report
For Period Ended March 31, 2023
Nouveau Life Pharmaceuticals, Inc.
Check One:
X Quarterly Report Interim Report
Address of Principal Executive Office:
3580 Wilshire Blvd, Suite 100
Los Angeles, CA 90010
Reason for Delay in Posting Financial Report State below in reasonable detail why the Annual/Quarterly Report could not be filed within the prescribed time period
prepare the quarterly financial statements and quarterly report
The Quarterly Report cannot be filed within the prescribed date because the issuer requires additional time to
Anticipated Filing Date: 5/22/2023
Person to contact regarding this notification: Date: 05/15/2023
Officer/Director Signature: Date: 05/15/2023
Instructions to post Notification of Late Filing in www.OTCIQ.com
1. Fill out this Notification of Late Fing form and convert the file to a PDF
2. Log in to www.OTCIQ.com and click "Add Financial Report" on the left hand navigation
3. Select Dissemination Date "Immediate 4. Under Report Type, select "Notification of Late Filing
Signature is Sang The Cho Name: Sang Tae Chal Title: CEO Signature /s/ Sang Tee Choi Name: Sang Tae Choi Title: GEO 5. Enter Period End Date corresponding to the quartentiscal year end date for which this Notice is being filed 6. Click "Browse" and select the PDF saved in step 1 above. 7. A preview of the document will appear next. Please make sure to review the entire document & scroll down to click the "Submit" button. Your Notification of Late Filing will appear within a few minutes on otomarkets.com Alterative Reporting companies on the Pink Current tier may utilize the Notification of Late Filing to receive the extension. The Notification must be submitted by the applicable reporting deadline to qualify for the OTCQB and OTCQX non-SEC reporting companies may also post this document to remain compliant with OTC reporting requirements Conditional Fang Relief for Companies Affected by the Coronavin: Issuer must specifically disclose a summary of why relief is needed in the Notification of Late Filing in order to receive the 45 day extension
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM